Business Operations Update
GAITHERSBURG, Md., March 8, 2024 – Emergent is proud of its more than twenty-year partnership with the United States government to develop and deliver medical countermeasures (MCMs) to address a...
Emergent BioSolutions Announces Shelf-Life Extension From 36 Months (Three Years) to 48 Months (Four Years) for NARCAN® Nasal Spray
With its proprietary four-year stability data, Emergent prioritized the shelf-life extension of NARCAN® Nasal Spray to help combat the opioid overdose epidemic GAITHERSBURG, Md., January 18, 2024...
ACAM2000®, (Smallpox Vaccine (Vaccinia Virus, Live)) and TEMBEXA® (brincidofovir) Receive EUNDS Approvals by Health Canada
GAITHERSBURG, Md., December 13, 2023 – Emergent (NYSE: EBS) today announced that this month, both ACAM2000® (Smallpox Vaccine (Vaccinia Virus, Live)) and TEMBEXA® (brincidofovir) tablets and oral...
Emergent BioSolutions Submits Supplemental Biologics License Application Seeking U.S. FDA Approval of ACAM2000®, (Smallpox (Vaccinia) Vaccine, Live) for Immunization Against Mpox
GAITHERSBURG, Md., November 7, 2023 – Emergent (NYSE: EBS) has recently submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval...
A Statement on Emergent’s Camden Manufacturing Facility Regulatory Status
GAITHERSBURG, Md., October 5, 2023 – Emergent (NYSE: EBS) received important communications from the U.S. Food and Drug Administration (FDA) regarding its Camden drug product manufacturing facility...
Emergent’s Statement Regarding the Passing of a Director of the Board
GAITHERSBURG, Md., August 16, 2023 – Emergent (NYSE: EBS) shares with deep sadness that Dr. Jerome Hauer, long-time member of Emergent’s Board of Directors and public health pioneer, passed away...
Emergent BioSolutions Announces the Execution of a Contract Option to Deliver ACAM2000® (Smallpox (Vaccinia) Vaccine, Live) into the Strategic National Stockpile
Order is for approximately $120 million of smallpox vaccine for delivery in 2023 Reaffirms ACAM2000® is a key component of the U.S. preparedness stance against the threat of smallpox Contract option...
Emergent’s Statement Regarding its Amended Credit Agreement
GAITHERSBURG, Md., May 17, 2023 – Emergent (NYSE: EBS) completed an amendment and extension of maturity of its existing syndicated credit agreement on May 15, 2023. We believe this revised...
Emergent’s Statement on Over-the-Counter Access, Availability and Pricing of NARCAN® Naloxone HCl Nasal Spray 4 mg
On the heels of last month’s FDA approval of NARCAN® Naloxone HCl Nasal Spray 4 mg for the over-the-counter (OTC) use of opioid overdose emergency, Emergent is committed to increasing awareness of...
Emergent BioSolution’s Statement on the Status of its Credit Facility and the Sale of its Travel Health Business
GAITHERSBURG, Md., April 17, 2023 – Emergent BioSolutions (NYSE: EBS) previously announced that it has entered into an agreement to sell its travel health business to Bavarian Nordic (BVNRY) for a...
Emergent BioSolutions Sponsors Manufacturing Day 2022, Declaring Manufacturing Matters & Inspiring New Generation of Talent
NAM and MI Celebrate #MFGDay2022 to Give Students Inside Look at Modern Manufacturing, Emergent Leaders Tour Lansing, Michigan Manufacturing Site with Local High School Students Washington, D.C. –...
Emergent BioSolutions Statement on the Status of its Camden Manufacturing Facility
GAITHERSBURG, Md., August 12, 2022 – Emergent (NYSE: EBS) received a communication from the FDA on August 10, 2022. That communication included the issuance of a warning letter. We share the...